Surgical Oncology of the Esophagus and Digestive Tract Unit, Surgical Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padua, Italy.
Medical Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
BMC Gastroenterol. 2022 Jan 10;22(1):17. doi: 10.1186/s12876-021-02084-x.
We report the first case of a patient affected by peritoneal metastases from colon cancer, arising in the context of Lynch syndrome with pathological complete response. The patient was treated with immunotherapy and cytoreductive surgery. This paper discusses the implications of these novel therapies for the management of PM.
A 50-year-old man affected by Lynch syndrome was referred to our institution for metachronous peritoneal recurrence of ascending colon adenocarcinoma. As a second-line treatment, he received Nivolumab therapy with stable disease. Patient underwent cytoreductive surgery with residual disease and a pathological complete response. Flow cytometry described a particular immune sub-population response. There was no evidence of disease progression after nine months.
This is the first report of a Lynch patient affected by peritoneal metastases of colorectal cancer, treated with cytoreductive surgery (CRS) and resulting in a pathological complete response after immune checkpoint inhibitors treatment (ICIs). This case report may suggest that patients with peculiar immunological features could benefit from a tailored approach, since "classical" CRS paradigms may not effectively predict the clinical outcome. Further large-scale studies are needed to determine the correct operative management of such patients (tailored or "standard" CRS), defining the correct surgical timing and eventual discontinuation of ICI therapy after surgery.
我们报告了首例林奇综合征合并病理完全缓解的结肠癌腹膜转移患者。该患者接受了免疫治疗和细胞减灭术治疗。本文讨论了这些新疗法对腹膜转移管理的意义。
一名 50 岁的男性患者患有林奇综合征,被转诊至我院治疗升结肠癌的异时性腹膜复发。作为二线治疗,他接受了纳武利尤单抗治疗,病情稳定。患者接受了细胞减灭术,仍有残余肿瘤,病理完全缓解。流式细胞术描述了一种特殊的免疫亚群反应。九个月后无疾病进展证据。
这是首例林奇综合征患者患有结直肠癌腹膜转移,接受细胞减灭术(CRS)和免疫检查点抑制剂治疗(ICIs)后病理完全缓解的报告。该病例报告可能表明,具有特殊免疫特征的患者可能受益于个体化治疗方法,因为“经典”CRS 方案可能无法有效预测临床结局。需要进一步的大规模研究来确定此类患者的正确手术管理(个体化或“标准”CRS),确定正确的手术时机和手术后免疫检查点抑制剂治疗的最终停药时间。